You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Digestive tract conditions
  5. Inflammatory bowel disease

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy

  • Technology appraisal guidance
  • Reference number: TA352
  • Published:  26 August 2015
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Crohn's disease (moderate to severe) - vedolizumab: committee papers part 1

Crohn's disease (moderate to severe) - vedolizumab: committee papers part 1 Crohn's disease (moderate to severe) - vedolizumab: committee papers part 1
08 January 2015
(10.23 Mb 50 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 09 January 2015

Back to top